Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Dat’AIDS Cohort

Background: We aimed to describe the prevalence and spectrum of second primary cancer (SPC) in HIV-positive cancer survivors. Methods: A multicenter retrospective study was performed using longitudinal data from the French Dat’AIDS cohort. Subjects who had developed at least two primary cancers were selected. The spectrum of SPCs was stratified by the first primary cancer type and by sex. Results: Among the 44,642 patients in the Dat’AIDS cohort, 4855 were diagnosed with cancer between 1 December 1983 and 31 December 2015, of whom 444 (9.1%) developed at least two primary cancers. The most common SPCs in men were non-Hodgkin lymphoma (NHL) (22.8%), skin carcinoma (10%) and Kaposi sarcoma (KS) (8.4%), and in women the most common SPCs were breast cancer (16%), skin carcinoma (9.3%) and NHL (8%). The pattern of SPCs differed according to first primary cancer and by sex: in men, NHL was the most common SPC after primary KS and KS was the most common SPC after primary NHL; while in women, breast cancer was the most common SPC after primary NHL and primary breast cancer. Conclusion: The frequency and pattern of subsequent cancers among HIV-positive cancer survivors differed according to the first primary cancer type and sex.

NANO-BASED THERAPY FOR TREATMENT OF SKIN CARCINOMA

Skin carcinoma is a frequently occurring cancer caused due to ultra violet rays of the Sun. It starts from normal skin cells but later on transforms into cells which undergo uncontrolled mitosis. Skin cancer is not as deadly as other cancers and has no metastasis and is not life threatening. Conventional chemotherapy has in general failed to treat skin cancer due to non specific targeting, which is accompanied by several side effects. Novel therapeutic approach based on nanotechnology have emerged as the best alternative for skin cancer treatment. We presented current scenario of nano based particulate drug carrier approaches for effective therapy for skin carcinoma by reducing side effects. This approach also reduces frequency of administration and improves patient compliance. Nanotechnology has emerged as the best alternative for conventional therapy for the effective treatment of skin cancer. Nanoparticles can specifically target skin carcinoma and are able to sustain drug release and reduce side effects to a greater extent.